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An  innova~ive  tool
The White Paper  on  Growth, Competitiveness and Employment acknc~100gG~
modern biotechnology as one  of  the fields offering the ;re&t~;~;
potential for innovation and growth. Its application could be 
particular benefit in areas such as healthcare, industrial chemic;;; 1."
food and feeds, agriculture and environmental clean-up sezvicem.
Moreover, the further development  of  biotechnology will requix'
increasing investment in supplies, services and hardware. This waul""
have a correspondingly positive effect on the employment situation.
CO1lll1lUrJi..ty  role
The European Community has been becoming increasingly involved in
biotechnology since the mid-1970s. ay funding research and developing ~
regulatory framework, it has sought to promote the competitiveness 
bio-industries, whilst also ensuring the safety  of  man and the
environment.
The Commission recognised, in its 1991 initiative, that biotechnology is a key technology for the future competitive development of th".
Comnrunity. As such, it will determine the extent to which commutd.t;f
industries remain world leaders in the development of innovatory
products. Although the main responsibility for competitiveness 
::::' (;;~
with the firms themselves, the Commission also took the  V.i.I'iJ"'l  t;,F.ri:
public authorities could help to stimulate competitiveness by
consistent and supportive approach in relevant areas. Th.i.1i' 'A'O'
entail the provision  of  financial support for DB.sic and 
"',p:;:
research and related infrastructure; the drawing up of  COh"'1?;:;nt
regulatory framework, based on a number  of  defined pr. l~:
(including protection of intellectual property); a renewed emp
:;.
$:Lz C
education and training; the stimulation of technology trans:i:' ;:; i:;
the facilitation of public understanding and consumer choice. 
:",
package of priority measures was subsequently approved.
A neW mpetl.1fS
'l'he 'iiJhite Paper confirmed the outstanding promise of biotechnC' 10931 i"
terms of growth, competitiveness and employment.
Taking account  of  the content and state of implementation  of  ne 1991
package, it gave new impetus to achieving a fuller realisation  or  th~
community inherent strength in biotechnology and to overcoming
existing constraints. Reinforcing conditions at both the ~&D and
marketing stages of biotechnology would increase its potential  fCl:
employment creation. By taking a number  of  specific steps, Europe'
competitiveness in this field will be further enhanced.
The present communication represents the Commission' s response to the
White Paper' s recommendations, and its structure has been designed so
as to follow the order in which these recommendations were list,ed. It
is based on the premise that the white Paper' s goals in relation to
biotechnology can be achieved onlr through close cooperation between
operators, users, Community Institutions, Member state authorities and
interest groups. The Commission recognises the important interest 
the European Parliament in developments in biotechnology and is ready ta establish the necessary dialogue on biotechnological is5ues, in
particular with the Parliament. It will also seek, as in the past, to
organise round-table discussions.REGULATORY FRAMEWORK
Int;roduct;i..on
Biotechnology involves the use of modern genetic engineering, which
will affect many different products and processes. The Community ' s
regulatory framework for biotechnology was designed, in the late 1980s, in order to provide the necessary legislation to ensure adequate
protection of health and the environment, while at the same time
creating the internal market for biotechnological products. It is based
On a number of principles, adopted in 19911) , which still retain their
validity (see ~nnex 1 for details).
The community is putting into place both "horizontal" and product
legislation containing a specific environmental risk assessment of
products containing or consisting of GKOs. (~n overview of the state of
play regarding current legislative activities is attached at Annex 1.
This framework has been built upon the knowledge available at that
time, when there was still considerable uncertainty as to safety and
the risks involved in the application of modern biotechnology. The
community adopted legislation aiming at a broadly preventative approach
as regards the use of modern biotechnology.
The White Paper concluded that the Community should be open to
reviewing its biotechnology regulatory framework, in order that the
full potential of modern biotechnology for jobs, investment and growth
can be realised.
Following this commitment, the Commission, in consultation with Member
state authorities, undertook such a review. Its objective was to
ensure that the safety requirements and administrative procedures are
appropriate to the risks for human health and the environment and
reflect acquired experience, advances in scientific knowledge and
established international practices. It also took account of the
existing regulatory frameworks on modern biotechnology used by its main
competitors, in particular the United states.
The  way ahead
In carrying out the review, the Commission paid special attention to
the wider range of knowledge and experience currently available, which
has increased understanding of the risks associated with genetic
modifications and increased confidence among scientists in the safety
of genetic engineering.
Much use has now been made of the technology in research laboratories and indu~trial facilities worldwide. From this knowledge and
experience, it may be concluded that the risks involved in the
contained use of GMMs are substantially less than were once foreseen.
For example, the potential for horizontal gene transfer resulting in
novel and harmful properties being acquired by microorganisms has not
1 ) SEC (91) 629been shown to present hazards to human health and the environment.
There is a growing confidence that the GMMs used in research and in
industrial production can be more precisely categorised, so that they
are unable to survive except in the special environment of the
experiment or process in which they are used. Experience has shown that
the majority of genetic modifications in contained facilities can be
done safely by applying good laboratory practice.
Worldwide, there have now been many deliberate releases of GMOS, mainly
with a number  of  well-known crop plants. 'rhis has led to an improved
understanding of the behaviour of these plants and their safety in
respect of human health and the environment. So far, such releases
have not given cause for concern, and evidence is accumulating to the
effect that genetically modified plants do not differ from non-modified
plants other than in the specific character conferred by the introduced
gene.
As part of its broader reflections, the Commission acknowledged that
the biotechnological regulatory framework is a factor impacting on
industrial competitiveness, which confirms the need for balanced and
proportionate regulatory requirements commensurate with the identified
risks.
It also noted the results of surveys indicating the important role that
the regulatory framework has to play in building public confidence in
biotechnology. This shows the need for  predictable and adaptable
regulatory system.
Taking these elements into account, the commission confirms its earlier
view that, in the future, the whole network of interrelated
biotechnological regulations needs to ensure that oversight is always
appropriate in relation to the risks involved, the building of public
confidence and to the competitive development of the industries
involved, while guaranteeing the protection of human health and the
environment. On this basis, the Commission is of the opinion that the
following two-track approach for the future development of the
biotechnological regulatory framework should be applied:
the exploitation of existing possibilities for revising
measures/procedures/degree of oversight/requirements, through use
of the "light" procedure of adaptation to technical progress
(regulatory Committee procedure). (internal amendment)
the bringing forward of amendments to existing legislation in order to incorporate changes which cannot be achieved by technical
adaptation while leaving the basic structure of the framework
intact (external amendment)
The Commission examined the application of the two-track approach in
greater detail for specific parts of the regulatory framework,
considering each such part on its particular merits. It came to the
conclusions outlined below.Di..rec~ive 90j219jEEC
mi..croorganiSlilS
~he cont=a.ined use eneticaLL modified
The review indicated that extensive use was made during the late 1970s
and the 1980s of genetically~modified microorganisms in laboratories
and industrial fermenters, from which substantial experience was
gained. This experience, together with the recommendations made by the
OECD, forms the scientific basis of the Directive.
The Commission identified, on the basis of the substantially increased
understanding of the risks associated with the use of GMMs in contained
circumstances, as mentioned above, the following objectives for further
action:
streamlining and easing of the administrative/notification/
consent requirements where this does not compromise safety;
ii) ensuring that the classification of the genetically modified
micro-organisms and of the activities in which they are used
are appropriate to the risks involved;
Hi) ensuring that the conditions of use are appropriate to the
risks involved;
iv) extension of the flexibility of the Directive so it can be more
easily adapted to technical progress by regulatory Committee
procedures.
In line with these objectives, this will mean that it will continue to
make full use of the inherent flexibility of the Directive (regulatory
Committee procedure), i. e. by:
preparing a Decision redefining the risk categories of GMMs through
the revision of Annex II;
revising the guidelines for classification as established under
Article 4. of the Directive as a result of the discussion
undertaken for amending the criteria of Annex II (see above);
further exploiting the possibilities to adapt safety assessment
parameters, containment measures and requir~d information for
technical progress.
The increased knowledge and experience mentioned above also gives 
clearer indication of the present administrative (notification) consent
requirements necessary to ensure safety for the different risk
categories of GMMs.
Taking into account the most up to date information, it may 
concluded that the existing administrative arrangements may be
lightened for activities presenting low risk to human health and the
environment, without jeopardising existing safety standards. This would also allow a greater focusing of attention on higher riskpoesibilitiee. However, ae the Directive doee not provide for euch
adaptatione, a number of specific amendmente muet be introduced, ae
followe:
replacing the coneent requiremente by record-keeping, or
notification for information purpoeee, for certain low-riek
acti vitiee;
replacing the explicit coneent requiremente by implicit coneent for
certain higher-riek activities;
reduction of time periode involved in implicit/explicit coneent
proceduree;
adapting  the  preeent riek claeeification eyetem for GMMe, in
accordance with new safety coneideratione.
removal of the differentiation between
laboratoriee and production plante.
activitiee reeearch
The Commieeion will propoee the poeeibility of adapting the definitione
contained within the ecope of the Directive via a Committee procedure,
ae ie, for example, at preeent foreeeen in the caee of pharmaceutical
legislation.
The Commieeion will conduct the necessary broad consultations with
operators, users, Member state authorities and interest groups in order
to propose amendments before the European Council to be held in Essen
by the end of 1994.
Directive 90/220/EEC on the deliberate release or genetically modified
organisms  to  the environment
The commission has made a number of technical adaptations to the
Directive to reflect the evidence acquired from the wide number of GMO
releases in the plant area, which were shown not to pose any specific
risks. These measures seek to improve uniform application, streamline
and simplify the procedures and reduce the obligations on the notifiers
while maintaining the appropriate protection of health and the
environment. These activities are the following:
Commission Decision revising the notification information
requirements of Annex II of the Directive, reducing them
significantly for releases of plants (95% of releases) (April 94).
A Commission Decision revising the Summary Notification Information
format reducing the information required for plants (April 94).
Commission Decision establishing criteria for introducing
simplified procedures under Article 6. (Oct. 93) for genetically
modified plants.
Preparation of  Commission Decision introducing specific
simplified procedures for releasee of plants (to be adopted by
June/July 94).
The Commission concluded, on the baeis of the progrese made in adapting
aspects of the Directive, that it is flexible enough to satisfy current
needs for adaptation to technical progress and simplification of
procedures. In the short term, it will fully exploit the existing
possibilities in this area.Biotechnology is a fast-moving and continually evolving technolOgy, and
the Commission recognises that there are aspects of the Directive that
might be improved. It is not, however, possible at present to detail
the precise nature of these improvements, as further experience is necessary in order to determine the right balance between the need for
safety, public reassurance and the minimum restraint on industry and
research work.
Hence, on the basis of future experience and 
scientific knowledge, the Commission will carry out a further review of the Directive during the
first half of 1995. This review will assess the need for proposals in
relation to:
extending the flexibility of Directive 90/220/EEC, so that its scope and the procedures to be followed are always appropriate to
the risks involved, and are easily adaptable;
strengthening more uniform decision-taking between Member states in
the case of research and development releases;
introducing further opportunities for notifiers (industry and researchers), so that they can benefit more from the existence of a
uniform Community system;
facilitating
leghlation.
the link between this Directive and product
Other legislation
The Commission has noted that, to date, one specific piece of product
legislation, namely for medicinal products of biotechnology, is in force. As from 1 January 1995, this will be replaced by a centralised procedure which will result in a Community-wide marketing authorisation. This new piece of legislation is the result of a streamlining of existing marketing authorisation procedures so that patients can benefit from new innovative medicinal products simultaneously in all Member States, while at the same time safeguarding maximum standards of public health.
In respect of other product-based regulations which contain or will
contain an environmental risk assessment similar to that in Directive
90/220/EEC, one other such piece of legislation 
(namely, additives in feeding stuffs) has been adopted - which will enter into effect as from
1 October 1994 - and a further two (on novel foods and seeds) are under
discussion before the other institutions. The rapid adoption by the
Council of this legislation, as an essential part of the overall framework, is seen as a matter of urgency. The Commission will continue to make efforts to arrive at this and to ensure its proper implementation, by drawing upon experience and knowledge already available.It will. as a matter of urgency, make a proposal for an amendment to
Council Directive 91/414/EEC on the placing of plant protection
producte on the market in order to complete the environmental risk
assessment, already provided for in the Directive, with the technical
complements which are neCessary to cover adequately plant protection
products containing or consieting of GMMs. A fast track procedure for
certain low risk plant protection products, including biological plant
protection products. whether derived from eMMa or not, will also be
proposed.
In relation to the legislation to protect workers from the risks
related to exposure to biological agente at work, the Commission will
prees Member states for a more rapid transposition.
The review again demonstrated the need for adequate patent protection
for inventione, as an important condition for attracting investments in
biotechnology. The Commission re-emphasiees therefore that Community
legislation, which has been under discussion since 1988 and 1990
respectively, in the area of intellectual property (patents for
biotechnology inventions and plant variety rights) should be adopted as
a matter of urgency. By doing eo, an important gap in the regulatory
framework will be closed.
The same applies to the draft modification of the seed marketing
directives aiming at integrating the environmental risk assessment in
the established variety acceptance procedure.
The Commission will seize opportunities - as is foreseen, at the end of
1997, for example, in the legislation for medicinal products - as
regards further eimplification and/or streamlining of procedures of the
biotechnology regulatory framework as part of ite general policy in
this area as stated in the White Paper. An ongoing review of the
biotechnological regulatory framework shall be carried out as new
scientific knowledge and the emerging regulatory practice of major
international competitors indicates that this is necessary or
desirable.
STRENGTHENING OF SCIENTIFIC ADVICE
The White Paper recognised the importance of scientific advice
available to the Commission, which is particularly relevant in the
field of biotechnology with applications in a broad range of areas. At
present, it is therefore aeeeeeing whether there is  need for
reinforced scientific input to regulations, for example, in view of an
appropriate implementation of product legislation containing a specific
environmental risk assessment for products consisting of or derived
from GMOs. This assessment will also take account of the work of
existing advisory scientific committees at Community level and that
carried out by a number of national advisory Committees on biosafety or
genetic modification providing advice at national level. A meeting will
be organised between the Commission and the chairpersons of these
scientific committees to share experiences and to identify whether
there are further needs in the area. A European Science and Technology
Assembly is being set up to assist theCommisslon in the conception and
implementation of all Community reeearch and technological development
policies, including those relating to biotechnology. This will further
strengthen the links between the Commission and the research world.RESEARCH AND DEVELOPMENT
One of the greatest resources for the European biotechnology industry
is ready access to a well-established science base and a highly-skilled
workforce. A recent survey of some 400 new biotechnology companies
indicated that, generally speaking, they have grown up around areas of
academic excellence. This vital resource of innovation and skills, much
of it funded by governments, is also readily available to Europe large pharmaceutical and chemical companies, either via strategic
partnerl5lhips or directly-funded research. Experience, however, has
shown that, despite this, Member States need to give greater
recognition to the importance of the science base for biotechnology, as
has been done elsewhere. Furthermore, increased coordination is needed
between and within Member States' research programmes to minimise
wasteful duplication and to maximise collaboration, with the aim 
improving the efficiency of R&D expenditure.
Co~ty ini~iativeB
TO these ends, the Commission has recently proposed considerably
expanded research programmes activity within the area of Life Sciences
and Technologies: biotechnology (552 MECU), biomedecine and health (336
MECU) and agriculture and fisheries (684 MECU) under the Fourth
Framework Programme. This total proposed expenditure of 1572 MECU
signifies an increase in budget of 741 MECU in comparison to the
relevant programmes as included in the third Framework Programme.
The Commission realises that the European Union as a whole is not
matching research and development expenditure made elsewhere. However,
it is compensating for this by focusing on the most vigorous R&D areas
and on increasing coordination between the Member States ' and the
Community' s research programmes.
To improve these aspects, the three specific Programmes in the Life
Sciences and Technologies area propose three mechanisms:
Areas offering the highest potential returns on R&D in the short to
medium term will receive special priority for funding (concentrated
financial support). This will often involve a multi-disciplinary
and integrated approach.
Areas which are strategically important, but where limited financial support is available, will be supported by the
establishment of networks aimed at coordinating and building upon
Member states ' research programmes.
Areas which are essential to the exploitation of the life sciences,
but which may require special attention in respect of other factors
such as socio-economic or ethical issues, will be addressed by
horizontal activities. These will involve the key players and users
in dialogue aimed at socially acceptable solutions and a well-
informed public.
By the rapid adoption of the three specific programmes and through the
implementation of the above mentiened mechanisms, the Commission
expects to achieve a fuller realisation of the Community' s inherent
potential in biotechnology R&D.BIOTECHNOLOGY AND SMES
As shown by previous major technological advances, small and medium
sized enterprises play vital role in the early stages of
technological innovation and diffusion. This sector is growing, and a
number of important firms have been established. In terms of numerical
importance, SMEs specialising in modern biotechnology are located in the UK, France, the Netherlands, Denmark and Germany, and focus
primarily on the therapeutic and diagnostic fields of research and
production.
ColllllnH1ity lfiIupport
recognition of the important role of small and medium sized
enterprises has led many Member states to encourage the development of
the SME sector. Building on this, the White Paper has set out
guidelines for an integrated programme, whose focuS is on three major
themes: improving access to finance and credit facilities, support for
cooperation between firms and support for improvements in management
quality.
These objectives respond in large measure to the needs of the .small
and medium sized biotechnology enterprises. Like other SMEs, these
firms face difficulties in accessing private sector sources of funds,
whether from financial intermediaries, equity market or venture
capital. Small and medium sized biotechnology firms have a particular
need for industrial and financial partners when starting up.
other specific characteristics of biotechnology SMEs are the need for
and availability of high-tech scientific input and the need to overcome
hurdles quickly in bringing inventions and innovations onto the market. In view of this, the Fourth Framework R&D Programme opens up
opportunities:
for facilitating the participation of SMEs, irrespective of their
RTD capability, in community R&D programmes, via the implementation
of a special procedure based on the experience of CRAFT activities;
for encouraging the establishment of industrial platforms. These
consist of groups of European companies associated with specific
projects under the Community research programmes, with preferential
access to their results~
for demonstrations. The application of the innovative results of
research in the life sciences area will be addressed through well
targeted and pre-competitive demonstration activities. This will
enhance the attractiveness of new biotechnology applications;
for helping SMEs to find suitable partners to carry forward
innovative applications of biotechnology and to establish trans-
national networks for technology transfer.
science parks
The characteristics that biotechnology SHEa share with other science-
based st4Es underlie the emergence of science parks at the combined
initiative of the Sl4Es themselves and universities, in collaboration
with local and regional authorities. Up to one-third of biotechnology
SMEs in the Community are located in science pa.rks. With the stea.
entry of nelri' biotechnology firms, some 59 of Ute 250 science parks in
the community now contain an important biotechnology component.Science parks facilitate the process of technology innovation and
diffusion and offer a number of advantages for S~s. For example, they
provide easy and close access to science facilities, which enables the
SME to have a "window on the technology" and to be informed on the most
up-to-date developments. The costs involved in seeking venture or
investment capita,l partners are considerably reduced for firms and
investors alike; sourcing of intermediates and laboratory materials is
facilitated; and labour mobility can be encouraged between academic
work and research applications.
This evident trend of growth, in the Community, of science parks with
a biotechnology component, mirrors a development already witnessed in
the USA in the past decade, where, by 1992, there were 81 dedicated
biotechnology centres, with some 730 firms, specialising primarily in
applied research.
Under the Programme for Innovation and Technology Transfer, SPRINT
1989/93 (Council decision 89/286/EEC), modest Community funding was
envisaged to support feasibility studies and expert assistance in
creating science parks that serve a market need and that cu:e able  attract firms. Presently the Commission is, following the
recommendations of the Communication on Cohesion and RTD Policy
undertaking a study to evaluate the need to create networks, the type
of network mast conducive to the optimal functioning of science parks
and collaboration between Technology Parks within the European Union.
T#Jh  WIIIId Idl9W  fuHl2f e*plnHiOItjQr\ Rf nppnrtlmHlt\s fnr inpre~8e,:t
cooperation between firms operating on the internal market, and henc~
would contribute to realising the objectives of the integrated
programme for SMEs.
THE BNVESTMIENT CUMA TE
Th€t importanoo of thlil Invlilitment climntlil to th411 tranaftH' of applied
rfilBEDIIU:ch ana product d~vglopm9nt to thl!!! C'ommurolalinatlon !Btagg is fully rlilcognised. In geners.l, the allocmtlvQ mechanism ln mlll'ltel
economies im q;fflclent in shifting investment flows and factors lowarda
sectors experiencing, or llk.iIly to IiIxpc9l:1Iiln(~e h!lJh 'Jrowth, as with
certain areas of application of biotechnology.
While, in iii number of products deriv'0d from modern biotOlichnology,
market-driven growth is evident, there are others of major long-term
potential such as bioremediation products and new ranges of biosensors,
where growth is variable or modest. The result is that medicinal
products of biotechnology is the target domain of over 60% of the
current modern biotechnology firms, while bioremediation product
development occupies less than 5% of the existing firms. Investment
incentives in particular by Member States, within the existing
community framework, to improve the investment climate in these areas
are recommended. This would cover support for R&D activities, or the start-up Or expansion of business activities, together with the
establishment of sound technological clusters and a business-friendly tax climate. In doing so, Member states would strengthen Europe' s
competitiveness in high-value added future growth markets. For its part, the Community will, through the im~lementation of a newly-
proposed specific programme on the diffusion and exploitation of R&D
results (involving expenditure of 293 MECUs), help to overcome barriers
preventing the conversion of scientif ic achievements into commercial
successes.IPUBUC UNDERSTANDiNG
The introduction of any new technology, whether in the past or 
present, has raised critical reactions from the general public. This is
especially true of biotechnology, as it raises value-laden issues.
Surveys indicate that understanding of biotechnology varies widely
within the Community, as does the perception of the risks and benefits
of different applications.
The Commission has helped to bring about a number of initiatives to
raise public awareness, although it recognises that other public and
private bodies have primary responsibility in this area. The focus; for
the Community s activities has been the Life Sciences and Technologies
Research Programmes. The following actions will be reinforced;
analytical work concerning public attitudes, including the
Eurobarometer surveys. This is necessary in order to understand the
scale of the problem and the factors which lie behind it. Such work
will guide future awareness activities to be undertaken by the
commission, Member State governments and other interested parties
from the public and private sectors.
raising awareness among the main players. Building upon the
experience of analytical work, increased information will be
provided in a balanced and impartial ~lay to raise awareness in
industries where the commercial potential of the emerging
technology may not be well understood; in the public sector,
including government institutions, where policies and strategies
are developed; among the media communicating biotechnology to the
public; among scientists increasing public understanding of
science; and public interest groups and educators.
raising awareness and providing information to the general public.
A European Initiative in Biotechnology Education has been launched
and will be reinforced to provide teaching materials and expertise
to school teachers throughout the European Union. Other specialised
materials will be prepared and workshops, conferences and meetings
will be held to encourage dialogue and to aid openness.
The commission recognises that mode.rn biotechnology comprises many
varying .applications. In view of this, it is important that all parties
concerned develop reliable information on all aspects of these
applications, especially as regards their potential benefits and risks.
This involves illustrating innovative advantages as well as addressing
issues such as safety, ethics and environmental protection. It would,
however, like to stress that, ultimately, it is the market place which
decides the successful commercialisation of individual biotechnological
applications.
ETHICS
Genera~
Developments in biotechnology may raise questions of an ethical nature
in certain areas. There is concern about tampering with nature and
life, and -the White Paper stressed the need to ensure that these
questioM1 5..;::--2 .::ddressed and ldentified properly. J:n response to this,
elle Col"arnlsslor:l has reinforced the prattle of  tlva  Group of P,dvisers on
the Ethical Implications of Biotechnology, -thereby building on the
results achieved during the first two year term of the Group.;:;::,
u ,.~u..jh established in 1991, is concerned with:
the identification and definition
biotechnology;
the appraisal of the ethical
field of biotechnology, and
the individual;
ethical issues raised
aspects of ComrnQnity activities in the
their potential impa9t on society and
and advising the Commission as regards the ethical aspects of
biotechnology, with a view to improving public understanding.
So far, the group has given three opinions on the ethical
implications of the use of performance enhancers in agriculture and
fisheries, of medical products derived from hQman blood and 'plasma, and
of legal protection of biotechnological inventions. These opinions have
greatly assisted the Commission in formQlating its policy in these
areas.
The Group' s mandate has been renewed recently to increase the number of
advisers, and hence to make available a broader range of advice. It
consists of independent leading experts from several different branches
of science. It is the Group s intention to step up its contacts with
the general public and international organisations. At the same time,
it has also intensified its work programme and its Secretariat has been
reinforced. At present, opinions are under preparation on the ethical
aspects related to transgenic animals, gene-therapy and pre-natal
diagnosis, all of which will befinalised before the end of this year.
Because of its terms of reference, the Group has a unique place in the
EQropean Union. It is closely involved, in a consultative capacity, in
the elaboration of relevant Community policy, bQt is completely
independent. It is also able, at its own initiative, to examine any
topic touching on biotechnology.
Several activities such as workshops and seminars on legal and ethical
aspects related to biotechnological and biomedical research inclQding
their application in the agricultural sector are proposed under the
Fourth Framework Programme. These activities are related to more
general issues concerning biotechnology (patents, biodiversity, animal
models) and the application of classical rules of medical ethics
(informed consent, confidentiality, ethical review of research
protocols) to new fields of biomedecine like brain research, gene
therapy and neurotransplantation.
Biomedical ethics
In the past, the Commission has taken a number of initiatives to
clarify ethical issues in relation to biomedical and health research.
For example, the human embryo and research (HER) working group has
monitored the legal and practical aspects of research on human embryos
in the Member States and identified sectors where a consenSQS could be
reached. Two reports, on embryos before and after implantation, have
been published, and the state of legislation on embryo research waS
reviewed. Protection of embryos and !Specific issQes like pre-
implantation diagnosis will be the next tasks of this working groQP'
Moreover, the ESLA (Ethical, Social and Legal Aspects) working group
under the human genome analysis research progralllllle, has encoQraged
PQblic discQssion and made recommendations to the Commission on the
legal or other initiatives to be taken in this field.Research in all areas of biomedical ethics has been initiated under the
first B10medical and Health research programme, and the commission has
proposed to continue this under the new second specific Biomedical and
Health research programme. To this end, it intends to organise working
groups to prepare reports and surveys for the European Parliament and
Council of Ministers on relevant biomedical ethical issues. Targeted
workshops are to be held to identify and debate issue:e requiring
clarification and debate at an international level.
Int:ernational
An increasing number of international organisations have undertaken
initiatives to clarify the ethical issues related to the different kind of applications of biotechnology. In this respect the commission
attaches importance to the work of the Council of Europe towards the
preparation of a convention on Bioethics. The Commission is preparing a
Communication to the Council on its participation in this Convention.
CONCLUSIONS
The Commission considers that the application of modern biotechnology
will have a major impact on the development of a wide range of sectors.
Whilst naturally committed to guaranteeing maximum standards of safety
for man and the environment, it is of the opinion that, by taking a
number of specific steps, as a follow-up to the White Paper
recommendations, it will encourage the competitiveness of Europe
bioindustries. It counts upon the other Institutions, Member states and
interest groups to give force to these measures. The Commission
recognises the important interest of the European Parliament in
developments in biotechnology and is ready to establish the necessary
dialogue on biotechnological issues, in particular with the Parliament.
It will also seek, as in the past, to organise round-table discussions.
Taking account of the considerations outlined above,
upon the following:
it has decided
to implement a two-track approach as regards the future development
of the biotechnological regulatory framework i. e' to exploit fully,
where they exist, the inherent possibilities to adapt to technical
progress (via regulatory Committee procedure). At the same time, it
will bring forward amendments in order to incorporate changes which
cannot be achieved by technical adaptation while leaving the basic
structure of the framework intact. In line with this approach it
will, as regards
directive ~0/219/EEC on the contained use of GMMs, continue to
review Annexes II to  and conduct the necessary broad
consultations with operators, users, Member state authorities
and interest groups, in order to propose amendments in the
indicated areas before the European council at Essen so that the wide ranging available knowledge and experience is
incorporated in that directive. By doing so, its functioning
will be improved without jeopardising existing safety
standards.
directive 90/220/EEC on the deliberate release of GMOs, make
full use of the possibilities to adapt to progress and in
particular to simplify procedures. On the basis of ongoingxperience and scientific and technological '::evelopments, in
the first half of 1995 an evaluation will take place following
the objectives set out, whereby an assessment will be made of
the need for bringing forward amendments.
other parts of the regulatory framework, continue to press for
rapid adoption of the intellectual property protection
legislation as well as of product legislation containing an
environmental risk assessment similar to that of directive
90j220jEEC.  It will ensure adequate implementation of such
legislation by preparing guidelines drawing upon already
available expertise. The Commission, for its part, will, as a
matter of urgency, make a proposal for an amendment to Council
Directive 91/414/EEC, in order to complete the environmental
risk assessment of plant protection prodUcts derived from or
consisting of genetically modified microorganisms. A fast track
procedure for certain low risk plant protection products,
including biological plant protection products, whether derived
from GMMs or not, wi!l be proposed.
The rapid transposition of the workers' protection legislation
by the Member states is a matter of urgency.
An ongoing review of the biotechnological regulatory framework
shall be carried out as new scientific knowledge and the
emerging regulatory practice of major international competitors
indicates that this is necessary or desirable.
to identify and remedy the
advice at its disposal.
needs for strengthening scientific
to enhance the rapid adoption of, in particular, the proposed specific programmes for biotechnology, biomedecine, health and
agriculture and fisheries within the Life Sciences and Technologies
area. The concentrated financial support for areas offering the
highest potential returns on R&D and the establishment of networks
to build upon Member States ' research programmes are guarantees of
further developing Europe' S inherent strength in the area;
to facilitate the development of small biotechnology firms, given
their inherent advantages for developing new ideas and products. The Fourth Framework R&D Programme opens up opportunities for facilitating the participation of SMEs and for helping them to
carry forward innovative applications of biotechnology, both within
and outside science parks. Currently, the Commission is evaluating the need to creat~ networks, and the type of networks most
conducive to the optimal functioning of science parks. The
continued development of a favourable investment climate, following
existing Community guidelines, is also essential;
to facilitate public understanding of biotechnology through the
reinforcement of a number of outlined initiatives;
to reinforce the profile of the Group of Advisers
Implications of Biotechnology in order to clarify
laden issues related to biotechnology. Biomedical
will be similarly identified and debated.
on the Ethical
further value-
ethical issuesANNEX 1
STATE OF PLAY OF THE BIOTECHNOLOGICAL REGULATORY FRAMEWORK
The community s regulatory framework is composed of both "horizontal"
and product iegi$latiori (medic~nal products, additives used in animal
nutrition, plant . protection products, novel foods, seeds). Legislation
on intellectual property protection also forms part of this framework,
which is founded upon the following underlying principles;
Necessity: the Commission will propose legislation in this area
only if it is shown to be necessary by a thorough examination, on
a case-by-case basis, of the characteristics inherent in specific
biotechnological applications.
Efficient interaction; biotechnologically-derived products will be
subject to only one authorisation and assessment procedure before
being placed on the market.
Evaluation criteria: product evaluation will take place in
accordance with the three established criter.ia of safety, quality
and efficacy. The commission will normally follow scientific
advice. In exceptional cases, however, it reserves the right to
take a different view in the light of its general obligation to
take into account other community policies and objectives.
Adaptation to progress: the regulatory framework will be kept up to
date with scientific and technical progress. This is of particular
importance in a rapidly developing field such as biotechnology.
Standards: the development and existence of standards may be used to complement legislation, particularly on technical details of
good practice and safety procedures.
International obligations: the commission will ensure that all
decisions in the field of biotechnology will be in conformity with
international obligations, in particular with the provisions
resulting from the Uruguay Round negotiations.
The state of play regarding relevant legislation is as follows:
A. LEGISLATIOlf ALREADY ADO:PTBD
Horizontal" legislation
Council Directive 90/219/EEC of 23 April 19902) which covers any
contained .use of genetically-modified microorganisms (GMMs), both for
research and commercial purposes;
Council Directive 90/220/EEC of 23 April 19903) on experimental and
marketing-related aspects of genetically~modified organisms (GMOs) ,
2 )
3 )
OJ No L 117, 8. 1990, p. 1
OJ No L 117, 8. 1990, p. 15v.lhich covers any R&D release of these organisms into the environment
and contains a specific environmental risk assessment for the placing of any product containing or conl$isting of such organisms onto the
market;
Council Directives 90/679/EEC of 31 December 19904) and 93/88/EEC of
29 October 19935) , which provide a minimum requirement designed to
guarantee a better standard of safety and health as regards the
protection of workers from the risks of exposure to biological agents.
Member states have transposed or are at the final stages of transposing
Directives 90/219/EEC and 90/220/EEC, and competent authorities have
been appointed in all Member states. Legislation has yet to be adopted
in Greece and Luxembourg, and has nearly been completed in Spain. In
Ireland, the specific regulations putting into effect the framework
enabling legislation have still to be adopted. Over 250 research and
development releases have been notified under Directive 90/220/EEC to the Commission and have taken place, the vast majority of which
concerned plants. These releases were in Belgium (60), Denmark (11),
Germany (10), Spain (8), France (78), Italy (18), the Netherlands (32),
Portugal (4) and the United Kingdom (35).
Three products have so far been cleared under the 90/220/EEC system.
As regards Directives 90/679/EEC and 93/88/EEC, the transposition has
yet to be widely realised.
Product legislation
In respect of the other main part of the regulatory framework, namely,
specific product legislation, the situation is as follows:
Council Directi.ve  931114/EC,  amendi.ng Directive 70/524/EEC on
additives in feeding stuffs. This amendment introduced new categories of additives, including, among others, additives containing or
consisti.ng of GMOs into the existing legislation: the amendment will
enter into effect as of 1 October 19946);
Council Directive 93/41/EEC, repealing Directive 87 /22IEECon the the
approximation of national measures relating to the placing on the
market of high-technology medicinal products, particularly those
derived from biotechnology: the legislation will enter into effect as
of 1 January 19957) . Under the 1987 procedure about 50 medicinal
products of biotechnology have been approved;
Proposal for a Directive to amend Directive 91/414/EEC8) on the
placing on the market of plant protection products: this Directive
provides for a specific procedure for evaluating the environmental risk
of GMM plant protection products to be included in the Directive. The
commission is preparing a Proposal to that end.
The Commission has proposed to the COuncil to extend, for the lifetime
of the milk quotas, the present moratorium on the placing on the market
4 )
5 )
6 )
7 )
OJ No
OJ No
OJ No
OJ No
OJ No
L 374,
L 268,
L 334,
L 214,
L 230,
31.12. 1990, p. 1
29. 10. 1993, p. 71
31. 12. 1993, p. 24
24. 1993, p. 40
19. 1991, p. 1and administration of bovine somatotropin (BST). The Council has
adopted a Decision extending the morator.ium for one year, to allow time
for a detailed examination of all of the available information on
BST9) .
B . PROPOSALS NOT YET ADOPTED
Proposal for a Council Regulation concerning novel foods and novel
foods ingredientsl0);
Proposal to modify existing seed marketing
particular Directives 70/457/EEC and 70/458/EEC
varietiesll) ;
directives, and in
on the acceptance of
Draft Council
Inventions12) ;
Directive Legal Protection Biotechnological
Draft council Regulation on community Plant Variety Rights
13)
9)  OJ No L 332, 31. 12. 93, p. 72
10) COM (92) 295 and COM' (93) 631 Final
11) COM (93) 598
12) OJ No C 10, 13. 1989, p. 3 and COM(92) 589 final
13) CDM(90) 347 and COM(93) 104